Studies of TCR, and BCR profiles in multiple cancer types have shown that TCR and BCR profiles can be used as predictive biomarkers of response to treatment with CTLA-4 or PD-1 inhibitors (19, 20, 22). Here, PDCD1 is linked to cancer.